Literature DB >> 19130291

Sepiapterin reductase deficiency in a 2-year-old girl with incomplete response to treatment during short-term follow-up.

K Kusmierska1, E E W Jansen, C Jakobs, K Szymanska, E Malunowicz, D Meilei, B Thony, N Blau, J Tryfon, D Rokicki, E Pronicka, J Sykut-Cegielska.   

Abstract

Sepiapterin reductase (SR) catalyses the last step in the tetrahydrobiopterin biosynthesis pathway; it converts 6-pyruvoyl-tetrahydropterin (6-PTP) to BH(4) in an NADPH-dependent reaction. SR deficiency is a very rare autosomal recessive disorder with normal phenylalanine (Phe) concentration in blood and diagnostic abnormalities are detected in CSF. We present a 16-month-old girl with SR deficiency. From the newborn period she presented with an adaptation regulatory disorder. At the age of 3 months, abnormal eye movements with dystonic signs and at 4.5 months psychomotor retardation were noticed. Since that time axial hypotonia with limb spasticity (or rather delayed reflex development), gastro-oesophageal reflux and fatigue at the end of the day has been observed. Brain MRI was normal; EEG was without epileptiform discharges. Analysis of biogenic amine metabolites in CSF at the age of 16 months showed very low HVA and 5-HIAA concentrations. Analysis of CSF pterins revealed strongly elevated dihydrobiopterin (BH(2)), slightly elevated neopterin and elevated sepiapterin levels. Plasma and CSF amino acids concentrations were normal. A phenylalanine loading test showed increased Phe after 1 h, 2 h and 4 h and very high Phe/Tyr ratios. SR deficiency was confirmed in fibroblasts and a novel homozygous g.1330C>G (p.N127K) SPR mutation was identified. On L-dopa and then additionally 5-hydroxytryptophan, the girl showed slow but remarkable progress in motor and intellectual ability. Now, at the age of 3 years, she is able to sit; expressive speech is delayed (to 1 1/2 years), passive speech is well developed. Her visual-motor skills, eye-hand coordination and social development correspond to the age of 2 1/2 years.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19130291     DOI: 10.1007/s10545-008-1009-4

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  14 in total

Review 1.  Neurochemistry and defects of biogenic amine neurotransmitter metabolism.

Authors:  K Hyland
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

2.  Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia.

Authors:  L Bonafé; B Thöny; J M Penzien; B Czarnecki; N Blau
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

3.  Dopa-responsive hypersomnia and mixed movement disorder due to sepiapterin reductase deficiency.

Authors:  Jennifer Friedman; Keith Hyland; Nenad Blau; Mia MacCollin
Journal:  Neurology       Date:  2006-12-12       Impact factor: 9.910

4.  Sepiapterin reductase deficiency: clinical presentation and evaluation of long-term therapy.

Authors:  Bernard Echenne; Agathe Roubertie; Birgit Assmann; Thomas Lutz; Johann M Penzien; Beat Thöny; Nenad Blau; Georg F Hoffmann
Journal:  Pediatr Neurol       Date:  2006-11       Impact factor: 3.372

5.  Oral phenylalanine loading test for the diagnosis of dominant guanosine triphosphate cyclohydrolase 1 deficiency.

Authors:  Eduardo López-Laso; Aida Ormazabal; Rafael Camino; Francisco J Gascón; Juan J Ochoa; María E Mateos; María J Muñoz; Juan L Pérez-Navero; José I Lao; María A Vilaseca; Rafael Artuch
Journal:  Clin Biochem       Date:  2006-04-19       Impact factor: 3.281

6.  Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder.

Authors:  B G R Neville; R Parascandalo; R Farrugia; A Felice
Journal:  Brain       Date:  2005-07-27       Impact factor: 13.501

7.  Diagnosis and treatment of neurotransmitter disorders.

Authors:  Phillip L Pearl; Thomas R Hartka; Jacob Taylor
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.598

Review 8.  Inborn errors of neurotransmitter receptors.

Authors:  R Surtees
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

9.  Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia.

Authors:  Nico G Abeling; Marinus Duran; Henk D Bakker; Lida Stroomer; Beat Thöny; Nenad Blau; Jan Booij; Bwee Tien Poll-The
Journal:  Mol Genet Metab       Date:  2006-05-02       Impact factor: 4.797

Review 10.  Pediatric neurotransmitter diseases.

Authors:  Phillip L Pearl; Denise D Wallis; K Michael Gibson
Journal:  Curr Neurol Neurosci Rep       Date:  2004-03       Impact factor: 5.081

View more
  3 in total

1.  Sleep and rhythm consequences of a genetically induced loss of serotonin.

Authors:  Smaranda Leu-Semenescu; Isabelle Arnulf; Caroline Decaix; Fathi Moussa; Fabienne Clot; Camille Boniol; Yvan Touitou; Richard Levy; Marie Vidailhet; Emmanuel Roze
Journal:  Sleep       Date:  2010-03       Impact factor: 5.849

2.  Genotype-phenotype correlations in sepiapterin reductase deficiency. A splicing defect accounts for a new phenotypic variant.

Authors:  Luisa Arrabal; Libertad Teresa; Rocío Sánchez-Alcudia; Margarita Castro; Celia Medrano; Luis Gutiérrez-Solana; Susana Roldán; Aida Ormazábal; Celia Pérez-Cerdá; Begoña Merinero; Belén Pérez; Rafael Artuch; Magdalena Ugarte; Lourdes R Desviat
Journal:  Neurogenetics       Date:  2011-03-24       Impact factor: 2.660

Review 3.  Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies.

Authors:  Thomas Opladen; Eduardo López-Laso; Elisenda Cortès-Saladelafont; Toni S Pearson; H Serap Sivri; Yilmaz Yildiz; Birgit Assmann; Manju A Kurian; Vincenzo Leuzzi; Simon Heales; Simon Pope; Francesco Porta; Angeles García-Cazorla; Tomáš Honzík; Roser Pons; Luc Regal; Helly Goez; Rafael Artuch; Georg F Hoffmann; Gabriella Horvath; Beat Thöny; Sabine Scholl-Bürgi; Alberto Burlina; Marcel M Verbeek; Mario Mastrangelo; Jennifer Friedman; Tessa Wassenberg; Kathrin Jeltsch; Jan Kulhánek; Oya Kuseyri Hübschmann
Journal:  Orphanet J Rare Dis       Date:  2020-05-26       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.